$GMED
GLOBUS MEDICAL INC Stock $gmed

$gmed Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000123783117000031 Filed on August 03, 2017

Income Statement

Concept	2017 Q2	2016 Q2
Revenue	$152.4M	$137.5M
YoY Change	10.84%	2.93%
Cost Of Revenue	$37.20M	$32.73M
YoY Change	13.65%	0.47%
Gross Profit	$115.2M	$104.8M
YoY Change	9.96%	3.6%
Gross Profit Margin	75.59%	76.19%
Selling, General & Admin	$64.44M	$53.31M
YoY Change	20.87%	-2.19%
% of Gross Profit	55.94%	50.89%
Research & Development	$10.71M	$10.59M
YoY Change	1.12%	16.66%
% of Gross Profit	9.3%	10.11%
Depreciation & Amortization	$10.70M	$7.000M
YoY Change	52.86%	18.64%
% of Gross Profit	9.29%	6.68%
Operating Expenses	$77.82M	$66.84M
YoY Change	16.43%	4.5%
Operating Profit	$37.37M	$37.92M
YoY Change	-1.44%	2.4%
Interest Expense	$2.000M	$300.0K
YoY Change	566.67%	0.0%
% of Operating Profit	5.35%	0.79%
Other Income/Expense, Net	$2.186M	$418.0K
YoY Change	422.97%	-5.22%
Pretax Income	$39.56M	$38.34M
YoY Change	3.18%	2.31%
Income Tax	$10.89M	$12.53M
% Of Pretax Income	27.53%	32.68%
Net Earnings	$28.67M	$25.81M
YoY Change	11.09%	7.28%
Net Earnings / Revenue	18.81%	18.77%
Basic Earnings Per Share	$0.30	$0.27
Diluted Earnings Per Share	$0.29	$0.27
COMMON SHARES
Basic Shares Outstanding	96.16M shares	95.59M shares
Diluted Shares Outstanding	97.82M shares	96.43M shares

Balance Sheet

Concept	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$312.2M	$324.5M
YoY Change	-3.79%	62.41%
Cash & Equivalents	$88.74M	$95.34M
Short-Term Investments	$162.5M	$229.2M
Other Short-Term Assets	$6.400M	$16.60M
YoY Change	-61.45%	-77.54%
Inventory	$111.1M	$104.4M
Prepaid Expenses
Receivables	$95.49M	$74.71M
Other Receivables	$10.00M	$15.10M
Total Short-Term Assets	$535.1M	$535.4M
YoY Change	-0.06%	17.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$130.1M	$119.1M
YoY Change	9.28%	19.18%
Goodwill	$112.8M	$91.96M
YoY Change	22.62%	-1.71%
Intangibles	$90.04M	$32.99M
YoY Change	172.89%	-2.82%
Long-Term Investments	$60.90M	$65.60M
YoY Change	-7.16%	-19.41%
Other Assets	$1.051M	$302.0K
YoY Change	248.01%	-72.6%
Total Long-Term Assets	$459.9M	$334.0M
YoY Change	37.67%	7.79%
TOTAL ASSETS
Total Short-Term Assets	$535.1M	$535.4M
Total Long-Term Assets	$459.9M	$334.0M
Total Assets	$995.0M	$869.5M
YoY Change	14.44%	13.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.29M	$11.63M
YoY Change	40.1%	-36.55%
Accrued Expenses	$41.71M	$47.89M
YoY Change	-12.91%	-20.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$69.06M	$70.28M
YoY Change	-1.73%	-23.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.802M	$1.715M
YoY Change	5.07%	-49.45%
Total Long-Term Liabilities	$1.802M	$1.715M
YoY Change	5.07%	-49.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$69.06M	$70.28M
Total Long-Term Liabilities	$1.802M	$1.715M
Total Liabilities	$89.71M	$89.95M
YoY Change	-0.26%	-25.99%
SHAREHOLDERS EQUITY
Retained Earnings	$686.3M	$578.4M
YoY Change	18.66%	25.6%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$905.3M	$779.5M
YoY Change
Total Liabilities & Shareholders Equity	$995.0M	$869.5M
YoY Change	14.44%	13.71%

Cashflow Statement

Concept	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	$28.67M	$25.81M
YoY Change	11.09%	7.28%
Depreciation, Depletion And Amortization	$10.70M	$7.000M
YoY Change	52.86%	18.64%
Cash From Operating Activities	$26.00M	$23.80M
YoY Change	9.24%	81.68%
INVESTING ACTIVITIES
Capital Expenditures	-$13.60M	-$10.70M
YoY Change	27.1%	-40.22%
Acquisitions
YoY Change
Other Investing Activities	-$34.30M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$47.90M	-$10.80M
YoY Change	343.52%	-77.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.700M	1.100M
YoY Change	236.36%	-42.11%
NET CHANGE
Cash From Operating Activities	26.00M	23.80M
Cash From Investing Activities	-47.90M	-10.80M
Cash From Financing Activities	3.700M	1.100M
Net Change In Cash	-18.20M	14.10M
YoY Change	-229.08%	-142.09%
FREE CASH FLOW
Cash From Operating Activities	$26.00M	$23.80M
Capital Expenditures	-$13.60M	-$10.70M
Free Cash Flow	$39.60M	$34.50M
YoY Change	14.78%	11.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001237831
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96291880	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	GLOBUS MEDICAL INC
CY2016Q4	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	734000	USD
CY2017Q2	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	1397000	USD
CY2016Q2	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	1000	USD
	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	5001000	USD
CY2017Q2	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	233000	USD
	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	5234000	USD
CY2016Q4	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	14108000	USD
CY2017Q2	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	9663000	USD
CY2016Q4	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	5972000	USD
CY2017Q2	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	10676000	USD
CY2016Q2	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	0	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	0	USD
CY2017Q2	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	4871000	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	4871000	USD
CY2016Q2	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	1794000	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	2437000	USD
CY2017Q2	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	333000	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	811000	USD
CY2016Q2	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	0	USD
	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	0	USD
CY2017Q2	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	42000	USD
	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	42000	USD
CY2016Q4	gmed	Intangible Assets Gross IntangibleAssetsGross	68431000	USD
CY2017Q2	gmed	Intangible Assets Gross IntangibleAssetsGross	100410000	USD
CY2016Q2	gmed	Non Cash Settlement Of Contingent Consideration NonCashSettlementOfContingentConsideration	1522000	USD
	gmed	Non Cash Settlement Of Contingent Consideration NonCashSettlementOfContingentConsideration	1522000	USD
CY2017Q2	gmed	Non Cash Settlement Of Contingent Consideration NonCashSettlementOfContingentConsideration	0	USD
	gmed	Non Cash Settlement Of Contingent Consideration NonCashSettlementOfContingentConsideration	0	USD
	gmed	Number Of Product Categories NumberOfProductCategories	2
	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	400000	USD
	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	5234000	USD
CY2017Q2	gmed	Share Based Compensation Number Of Stock Plans ShareBasedCompensationNumberOfStockPlans	3
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17472000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	16291000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	91983000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	95489000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1911000	USD
CY2017Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1400000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46401000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41707000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4671000	USD
CY2017Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5260000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	166711000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	181223000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1958000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1736000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8642000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5872000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	211725000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	224796000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7160000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2920000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5690000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3571000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7062000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2771000	USD
CY2017Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3645000	USD
CY2016Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	397000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	789000	USD
CY2017Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1809000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3591000	USD
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5469000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5338000	shares
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2017000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3887000	shares
CY2016Q4	us-gaap	Assets Assets	927637000	USD
CY2017Q2	us-gaap	Assets Assets	995014000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	513766000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	535129000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	157673000	USD
CY2017Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	162520000	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	60444000	USD
CY2017Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	60932000	USD
CY2016Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	-519000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	155000	USD
CY2017Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	617000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1005000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	811000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	26617000	USD
CY2016Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	22260000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	22531000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19849000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	15326000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	20339000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2300000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5700000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60152000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95342000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132639000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149669000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	35190000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	17030000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	785000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95929916	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96288899	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95929916	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96288899	shares
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25723000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	54038000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	28876000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	60151000	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	32731000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	64250000	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	37199000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	72799000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	1625000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-4238000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	30638000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	34974000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	7876000	USD
CY2017Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	8175000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13698000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22935000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.56
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.59
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	119000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	450000	USD
CY2016Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.327
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.343
CY2017Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.275
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.300
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23214000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20389000	USD
CY2016Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	69000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	140000	USD
CY2017Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	47000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	98000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	-800000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	800000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6725000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10374000	USD
CY2016Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-309000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-201000	USD
CY2017Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	448000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	996000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	105926000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	112769000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	104758000	USD
	us-gaap	Gross Profit GrossProfit	212503000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	115191000	USD
	us-gaap	Gross Profit GrossProfit	235400000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	38336000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	81947000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	39557000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	81971000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12530000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	28131000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10890000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24590000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	32214000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	35475000	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3800000	USD
CY2017Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	9986000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1707000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1660000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2624000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3172000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-5796000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-6825000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-10078000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4497000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3812000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4652000	USD
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	868000	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1114000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8506000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-14884000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1000	USD
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	841000	shares
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1657000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1404000	shares
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	61706000	USD
CY2017Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	90036000	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	602000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1098000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1590000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3008000	USD
	us-gaap	Interest Paid InterestPaid	2000	USD
	us-gaap	Interest Paid InterestPaid	21000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	88688000	USD
CY2017Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	82429000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	112692000	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	111108000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	13257000	USD
CY2017Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	18088000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	10747000	USD
CY2017Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	10591000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	4536000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	4962000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	2085000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	1855000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	95559000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	89714000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	927637000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	995014000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	79892000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	69061000	USD
	us-gaap	Loans Receivable Description Of Variable Rate Basis LoansReceivableDescriptionOfVariableRateBasis	LIBOR
CY2016Q2	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	3056000	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	3056000	USD
CY2017Q2	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	243000	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	243000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3175000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	677000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46931000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63522000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	78827000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	79425000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	25806000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	66840000	USD
	us-gaap	Operating Expenses OperatingExpenses	131734000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	77820000	USD
	us-gaap	Operating Expenses OperatingExpenses	157715000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	37918000	USD
CY2017Q2	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	30000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	53816000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	28667000	USD
	us-gaap	Net Income Loss NetIncomeLoss	57381000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	30000000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	80769000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	37371000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	77685000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10836000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8502000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	928000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1051000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-143000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-62000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	186000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2627000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	222000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	2772000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-83000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	222000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	209000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2770000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	60000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	284000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	23000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	143000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1819000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1802000	USD
CY2016Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	125000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	281000	USD
CY2017Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	148000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	282000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	418000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1178000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2186000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4286000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	31501000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	172886000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	119196000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20142000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25061000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14502000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5879000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	129495000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	102733000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	16602000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	9503000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3575000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5911000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	124229000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	130123000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	148000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	958000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-2000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10594000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20624000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10713000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21379000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	477000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	478000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	628899000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	686280000	USD
CY2016Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	6946000	USD
CY2017Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	6159000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	137489000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	276753000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	152390000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	308199000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53312000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	107110000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64438000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	131497000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5690000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7062000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4019000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.93
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1895000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4626000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2870000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4760000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	293000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1609000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.80
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4678000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.60
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	23.86
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.89
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.49
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	95216000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7741000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8698000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.08
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.20
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	25.01
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	38076000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.66
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2989000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	5830000	USD
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	3618000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	7160000	USD
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	57140000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M18D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	359000	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5911000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	832078000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	905300000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96426000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96359000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97818000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97483000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95585000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95491000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96161000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96079000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, write-down for excess and obsolete inventory, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results. </font></div></div>

Files In Submission

Name	View Source	Status
0001237831-17-000031-index-headers.html	Edgar Link	pending
0001237831-17-000031-index.html	Edgar Link	pending
0001237831-17-000031.txt	Edgar Link	pending
0001237831-17-000031-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gmed-20170630.xml	Edgar Link	completed
gmed-20170630.xsd	Edgar Link	pending
gmed-20170630_cal.xml	Edgar Link	unprocessable
gmed-20170630_def.xml	Edgar Link	unprocessable
gmed-20170630_lab.xml	Edgar Link	unprocessable
gmed-20170630_pre.xml	Edgar Link	unprocessable
gmed6301710q.htm	Edgar Link	pending
gmed63017ex101.htm	Edgar Link	pending
gmed63017ex311.htm	Edgar Link	pending
gmed63017ex312.htm	Edgar Link	pending
gmed63017ex32.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GMED
GLOBUS MEDICAL INC Stock $gmed

2017 Q2 Form 10-Q Financial Statement

#000123783117000031 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED GLOBUS MEDICAL INC Stock $gmed

2017 Q2 Form 10-Q Financial Statement

#000123783117000031 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED
GLOBUS MEDICAL INC Stock $gmed